Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose-escalation Study of PSMA ADC in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer.

Next Previous
Trial Profile

A Phase 1 Dose-escalation Study of PSMA ADC in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PSMA ADC (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Sponsors Progenics Pharmaceuticals

Most Recent Events

  • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
  • 14 Feb 2013 Updated results were presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium according to a Progenics Pharmaceutical media release. Results were also briefly summarised in the media release.
  • 28 Sep 2012 Results will be presented at the 2012 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics according to a Progenics Pharmaceuticals media release. Results were also briefly summarised in the media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top